Last reviewed · How we verify
Adoptive TIL-TCM transfer therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Adoptive TIL-TCM transfer therapy (Adoptive TIL-TCM transfer therapy) — Sizhen Wang.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adoptive TIL-TCM transfer therapy TARGET | Adoptive TIL-TCM transfer therapy | Sizhen Wang | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adoptive TIL-TCM transfer therapy CI watch — RSS
- Adoptive TIL-TCM transfer therapy CI watch — Atom
- Adoptive TIL-TCM transfer therapy CI watch — JSON
- Adoptive TIL-TCM transfer therapy alone — RSS
Cite this brief
Drug Landscape (2026). Adoptive TIL-TCM transfer therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/adoptive-til-tcm-transfer-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab